Conference on personalised cancer therapy

Barcelona: 3-4 December 2012

The organisers of the IDIBELL Cancer Conference (ICC) on Personalized Cancer Medicine – Manel Esteller, George Thomas, Cristina Muñoz- Pinedo and Sara Kozma – will present 21speakers for the event, all leading oncologists and cancer researchers, particularly those working in the study of genetic and epigenetic defects leading to the selection of cancer patients for new drug therapies. The meeting aims to highlight the latest understanding of biological mechanisms and natural history of cancer, thus providing novel targets for therapy, as well as to discuss the molecular mechanisms involved in the stratification of oncology patents according to the recently described molecular markers. Special focus: Epigenetics and DNA Repair and the metabolism and cell signalling areas with the updated clinical applications. Details: http://bocemtium.com

05.11.2012

News • Dual-barrier tumours

How colorectal cancer evades immunotherapy (and what to do about it)

Most patients with metastatic colorectal cancer do not respond to immunotherapy—but why? A new study shows how the tumours block the immune system through two complementary mechanisms.

News • Targeted drug activation

Ultrasound-triggered chemotherapy to reduce side-effects

Researchers explore how ultrasound waves can be used to activate chemotherapy drugs only in targeted areas, offering a new path toward safer, more effective cancer treatment.

Article • Hengrui Pharma charts its global strategy at ESMO

Meet the Chinese company advancing European oncology

Hengrui, one of China's leading pharmaceutical companies, is preparing to bring its cancer therapies to international markets. At the ESMO congress in Berlin, Yuting (Shelley) Liu, Head of China…